Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression
Abstract Lenvatinib, a multitarget kinase inhibitor, has been proven to be effective in the treatment of advanced hepatocellular carcinoma. It has been previously demonstrated that tumour associated macrophages (TAMs) in tumour tissues can promote HCC growth, invasion and metastasis. Furthermore, le...
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
BMC
2024-07-01
|
| Schriftenreihe: | BMC Cancer |
| Schlagworte: | |
| Online Zugang: | https://doi.org/10.1186/s12885-024-12680-1 |